Biofourmis, a digital therapeutics platform based in Boston, announces that it has acquired Switzerland-based Biovotion AG, a developer of a clinical-grade wearable biosensor platform. The acquisition includes all of Biovotion’s assets, including the Everion® biosensor and more than 60 global patents covering most of the wearable and sensor technology that exists for the arm or hand.
The acquisition of Biovotion enables Biofourmis to offer proprietary, clinical-grade wearables as part of its Biovitals® ecosystem.
Today, clinical-grade wearables are becoming integral across all areas of healthcare, offering continuous real-time physiological data formerly only available in clinical settings. Combining Biovotion’s wearables with Biofourmis’ digital therapeutics platform and its artificial intelligence (AI)-powered predictive analytics creates the digital therapeutics solution on the market.
Biofourmis’ FDA-approved software-based digital therapeutics are part of the growing Biovitals® ecosystem. The company claimed that they’re already being leveraged across multiple segments of healthcare and life sciences to predict and prevent adverse health events and to provide better outcomes for patients; to deliver personalised care and manage chronic conditions such as heart failure, COPD and coronary artery disease; to demonstrate the value of and potentially complement pharmacotherapy; to provide cost-effective solutions for payers; and to advance clinical research.
The lead product among Biovotion’s wearables is the clinical-grade Everion® device, which is a multi-sensor platform worn on the arm capable of measuring 22 parameters in real-time. Collected physiological data can include heart rate, inter-beat interval, respiratory rate, blood oxygenation, skin temperature and actigraphy (rest/activity cycles)—all gathered non-invasively.
Also Read: Healthtech startup Biofourmis secures US$35M Series B funding
Additional clinical and non-clinical parameters such as blood pulse wave, motion intensity, and steps, energy expenditure, sleep quality, and heart rate variability are also insights collected by Everion®.
Building on Everion’s current market-leading wearable, the next-generation Everion® device is already under development and will have the ability to capture additional vital parameters, including continuous blood pressure trends.
The multi-parameter physiology data captured from Everion® will be an integral component of Biovitals’® digital therapeutics products and pipeline to manage conditions such as heart failure, COPD, oncology, and pain. These products are tailored to help providers identify the best therapies for managing chronic conditions before patients’ health worsens, potentially reducing hospital readmissions and decreasing the need for emergency department visits to reduce costs.
The entire Biovotion team will be incorporated into the Biofourmis family under the name “Biofourmis AG” in Zürich, Switzerland.
Aside from acquiring Biovotion, the company also announces the strategic alliance with the global healthcare company Novartis.
Also Read: These 10 startups are changing the way Malaysians access healthcare and wellness
The partnership will see both companies collaborating on a commercial project for managing patients with heart failure (HF) beginning in Southeast Asia, with potential plans to expand globally.
The goal of the program is to improve clinical outcomes by using Biofourmis’ lead product BiovitalsHFTM, which captures data from wearable biosensors and leverages the FDA-cleared BiovitalsTM Analytics Engine to identify early signs of HF exacerbations to enable early interventions in patients with HF with reduced ejection fraction.
HF is a life-threatening, progressive disease with debilitating symptoms and is the top global cause of hospitalisations for patients older than age 65.
The program’s initial phase, which kicks off this month, is expected to be rolled out across Southeast Asian countries for recently discharged HF patients, with plans to scale across multiple geographies. Patients will be onboarded in a 3-month program at the point of discharge and sent home with a wearable biosensor called Everion® and the patient-facing companion mobile app BiovitalsHFTM to enable patients to remotely monitor their physiology parameters, report their symptoms, manage their medications, and securely communicate with their care teams.
The BiovitalsTM Analytics Engine then processes the data captured from patients in real-time, captures HF exacerbation in advance, and provides software-based therapeutic recommendations for clinicians and care teams to intervene early.
Biofourmis is currently led by Kuldeep Singh Rajput, CEO, and founder of Biofourmis.
It focusses on discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, advanced tools for clinicians to deliver personalised care, technology to demonstrate the value of and potentially complement pharmacotherapy, and cost-effective solutions for payers.
–
The post Digital therapeutics platform Biofourmis acquires Biovotion AG, partners with global healthcare company Novartis appeared first on e27.